WILMINGTON, Mass. — Charles River Laboratories and MEDIPOST Co. Ltd. have signed a non-exclusive memorandum of understanding to collaborate on GMP-compliant testing and related commercial and marketing efforts for cell therapy development.
Wilmington-based Charles River said the partnership will use its biologics and cell therapy testing capabilities to support MEDIPOST’s global cell therapy pipeline. The collaboration will begin in the Asia-Pacific and North American regions, with possible expansion into the Middle East and Europe.
The companies said the agreement is intended to support cell therapy development and commercialization by combining Charles River’s testing expertise with MEDIPOST’s clinical and commercial-stage cell therapy experience.
“We are excited to deepen our partnership with MEDIPOST and collaborate with a top global cell therapy developer, assisting at both clinical and commercialization phases,” said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River. “By collaborating with industry leaders, we aim to expand GMP testing capabilities and help ensure that safe, compliant products reach patients more efficiently.”
Charles River said it will provide biologics quality control, viral testing, release testing and other GMP-compliant services. The company said the work will support MEDIPOST from development through commercialization.
The companies said the non-exclusive MOU reflects a shared goal of improving development pathways for advanced biologics and accelerating access to cell therapies in global markets.
“We are pleased to announce this collaborative partnership with Charles River Laboratories, a true global-standard player and services provider in the field of biologics research and development,” said Antonio (Tony) Lee, Global President and Board Director at MEDIPOST.
“With over 14 years of commercial-stage allogeneic cell therapy product manufacturing and release experience, treating more than 36,000 patients within South Korea, MEDIPOST is now expanding into global regions starting with APAC and North America. Our partnership with Charles River will help us pave solid paths to efficient and compliant commercial pathways in multiple regulatory jurisdictions across the globe.”
